The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...

Hims & Hers executives struck a confident tone about the company's growth prospects on Monday as it launches new specialties and expands rapidly into international markets. | Investors are concerned ...

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here to read why HIMS is a Sell.

Novo Nordisk filed a lawsuit against Hims & Hers Health (NYSE:HIMS) over alleged patent infringement tied to compounded weight loss drugs. Hims & Hers withdrew its compounded semaglutide product ...

The Australian telehealth unicorn announced its $1.6 billion sale to New York-listed Hims & Hers last year, minting a string ...